To dance or not to dance: biosimilar strategies post Amgen v Sandoz
03-12-2015
Amgen dealt blow as FDA rules 'patent dance' optional
30-03-2015
Esin Deniz / Shutterstock.com
Parties are required to provide 180 days’ notice to a patent owner before marketing a biosimilar version of its drug, a US district court has ruled.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Amgen; Apotex; Neulasta; US District Court for the Southern District of Florida; BPCIA; patent dance
